BREYANZI safety profile

Jump to section:



Select serious adverse events1*

Pooled safety data from the TRANSCEND and TRANSCEND WORLD studies (N=213)

CRS
NT

*  Pooled results from two studies (TRANSCEND [017001] and TRANSCEND WORLD [JCAR017-BCM-001]) in 213 adult patients within the dose range of 60 x 106 to 120 x 106 CAR+ viable T cells with R/R large B-cell lymphoma who received a flat dose of BREYANZI.1
†  Lee criteria for grading CRS (Lee DW. Blood. 2014;124(2):188-95. Errata in Blood. 2015;126(8):1048 and 2016;128(11):1533).1
‡  NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) criteria for grading neurologic toxicities.1
§  3 patients who received BREYANZI had ongoing CRS at the time of death.1
¶  Ongoing.


CLINICAL TRIAL ADVERSE EVENTS

Pooled safety data from the TRANSCEND and TRANSCEND WORLD studies1

Adverse reactions observed in ≥10% of BREYANZI patients (N=213)

The Preferred Term of CRS is summarized as well as the individual symptoms of CRS. These include chills, decreased appetite, dizziness, dyspnea, fatigue, headache, hypotension, hypoxia, nausea, pain, pyrexia, tachycardia, tremor.

  • *  Includes heart rate increased, sinus tachycardia, tachycardia.
  • †  Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal rigidity, abdominal tenderness, gastrointestinal pain.
  • ‡  Includes fatigue, malaise.
  • §  Includes edema, edema genital, edema peripheral, generalized edema, localized edema, scrotal edema, peripheral swelling, swelling.
  • ¶  Includes hypogammaglobulinemia, immunoglobulins decreased.
  • **  Infections and infestations are grouped per MedDRA high level group term.
  • ††  Includes headache, head discomfort, migraine, sinus headache.
  • ‡‡  Includes amnesia, cognitive disorder, confusional state, depersonalization/derealization disorder, depressed level of consciousness, disturbance in attention, flat affect, hypersomnia, incoherent, lethargy, leukoencephalopathy, loss of consciousness, memory impairment, mental impairment, mental status changes, paranoia, somnolence, stupor.
  • §§  Includes dizziness, presyncope, syncope.
  • ¶¶  Includes tremor, essential tremor, resting tremor.
  • ***  Includes acute kidney injury, blood creatinine increased, renal failure, renal impairment, renal injury.
  • †††  Includes cough, productive cough, upper-airway cough syndrome.
  • ‡‡‡  Includes acute respiratory failure, dyspnea, dyspnea exertional, respiratory failure.
  • §§§  Includes dermatitis acneiform, erythema, rash, rash maculo-papular, rash pruritic.
  • ¶¶¶  Includes hypotension, orthostatic hypotension.
CLINICAL TRIAL LABORATORY FINDINGS

Laboratory findings from the TRANSCEND and TRANSCEND WORLD studies1

Grade 3 or 4 treatment-emergent laboratory abnormalities occurring in ≥10% of patients treated with BREYANZI (N=213)

*   Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.


efficacy profile of BREYANZI icon
Learn more about the
efficacy profile of
BREYANZI
dosing and administration of BREYANZI icon
Explore BREYANZI
dosing and
administration
PSP icon
Discover the Patient
Support Program for
BREYANZI

Reference:
1. BREYANZI Product Monograph. Bristol-Myers Squibb Company.